ClinicalTrials.gg
CompletedNCT04985682Updated Mar 7, 2024Results posted

A Study of ADVATE in People With Hemophilia A in India

A Phase 4 interventional study of ADVATE in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 5 sites in India. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
10th of 21
50 · median 50
Started
2022
the only one that year
Phase 4
8 of 21
1 open now
Registered
20th of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 4, and was the 20th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The main aim of this study is to learn more about side effects of Advate when given as standard treatment to people with hemophilia A who have already been treated.

The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. Participants will need to visit the study doctor 5 times in total during the study. During these visits, study data will be collected by the study doctor.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant or legally authorized representative (in case of study participants less than (\<) 18 years of age) gave written to participate in the study.
  • Participant of any age with hemophilia A.
  • Participant defined as a previously treated patient (PTP):

    • Participant aged greater than or equal to (>=) 6 years that has been previously treated with plasma-derived and/or recombinant FVIII concentrate(s) for a minimum of 150 exposure doses (EDs).
    • Participant aged less than \<6 years that has been previously treated with plasma-derived or recombinant FVIII concentrate(s) for a minimum of 50 EDs.
  • Participant as negative history of FVIII inhibitors and negative inhibitor at screening defined as less than 0.6 Bethesda units (BU) per milliliter (Nijmegen-modified Bethesda assay).
  • Participant is negative (HIV-); or human immunodeficiency virus positive (HIV+) with stable disease and cluster of differentiation 4 (CD4+) count >=200 cells per cubic millimeter (mm\^3), as confirmed by central laboratory at screening.
  • Participant is virus negative (HCV-) by antibody or polymerase chain reaction (PCR) testing (if positive, anti-body titer will be confirmed by PCR), as confirmed by central laboratory at screening; or hepatitis C virus positive (HCV+) with chronic stable hepatitis.
  • Participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant has known to mouse or hamster proteins or to any of the of FVIII (factor VIII) concentrates.
  • Participant has been diagnosed with bleeding disorder(s) other than congenital hemophilia A, such as acquired hemophilia A, von Willebrand´s disease (VWD) or thrombocytopenia ( count \<100,000 per milliliter).
  • Participant has received treatment for hemophilia A with non-FVIII products or concentrates (example, emicizumab [Hemlibra®]) in the 6 months prior to screening.
  • Participant has severe chronic hepatic dysfunction (example, >=5 times [ALT], aspartate aminotransferase [AST] or [INR] >1.5 as confirmed by central laboratory at screening).
  • Participant has planned or is likely to have, surgery during the study period.
  • Participant has a medical, psychiatric, or cognitive illness, or recreational drug or alcohol use that, in the opinion of the investigator, would affect participant's safety or compliance.
  • Participant currently receiving or is scheduled to receive during the course of the study, an immunomodulating drug (example, agents at a dose equivalent to hydrocortisone >10 milligram per day, or α-interferon) other than antiretroviral chemotherapy.
  • Participant has participated in another clinical study involving an product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  • Participant is a family member or employee of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Hemophilia A Group

    Participants with hemophilia A were treated with ADVATE according to a regimen determined by the treating physician at the study site and in accordance with the national product label under standard clinical practice for 6.7 months.

    Biological: ADVATE

Interventions

  • BiologicalADVATE

    Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. An SAE was defined as any untoward medical occurrence that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of present hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was a medically important event. Number of participants with SAEs (including FVIII inhibitor formation) that were at least possibly related to ADVATE were reported.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

Secondary outcomes

  1. Number of Participants With Non-serious Adverse Events (AEs) at Least Possibly Related to ADVATE

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. Number of participants with non-serious AEs that were at least possibly related to ADVATE were reported.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  2. Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Clinical laboratory parameters included hematology, clinical chemistry, viral serology, factor VIII (FVIII) antigen, FVIII activity, incremental recovery, and FVIII inhibitor. Clinical significance was judged as per Investigator's assessment.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  3. Total Annualized Bleeding Rate (ABR) With Prophylactic Treatment of ADVATE

    ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error was estimated using a generalized linear model (GLM). The total ABR is reported in this outcome measure.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  4. ABR With Prophylactic Treatment of ADVATE Categorized Based on Location of Bleed

    ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed sites (example, joint, soft tissue, muscle, other \[mouth, gums or nose\] are reported in this outcome measure.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  5. ABR With Prophylactic Treatment of ADVATE Categorized Based on Type of Bleed

    ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed cause (example, spontaneous, injury, and unknown) are reported in this outcome measure.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  6. Total Number of ADVATE Infusions Required During Prophylactic Treatment

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  7. Average Number of ADVATE Infusions Required Per Week During Prophylactic Treatment

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  8. Average Number of ADVATE Infusions Required Per Month During Prophylactic Treatment of Bleeding Episode

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  9. Total Body Mass Adjusted Consumption of ADVATE During Prophylactic Treatment

    Body mass adjusted consumption international units per kilograms (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  10. Average Body Mass Adjusted Consumption of ADVATE Per Week During Prophylactic Treatment

    Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  11. Average Body Mass Adjusted Consumption of ADVATE Per Month During Prophylactic Treatment

    Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  12. Overall Hemostatic Efficacy Rating of ADVATE for Treatment of Bleeding Episodes

    Overall hemostatic efficacy for treatment of bleeding episodes was rated on 4-point Likert scale as: excellent=full relief of pain and cessation of objective signs of bleeding after a single infusion, no additional infusion is required for the control of bleeding and administration of further infusion to maintain hemostasis would not affect the scoring; good=definite pain relief and/or improvement in signs of bleeding after a single infusion, possibly requires more than 2 infusions for complete resolution and administration of further infusion to maintain hemostasis would not affect the scoring; moderate=probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion, required multiple infusions for complete resolution; none=no improvement of signs or symptoms or conditions worsen.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  13. Number of ADVATE Infusions Required to Achieve Resolution of Bleeding Episodes

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

  14. Total Body Mass Adjusted Consumption of ADVATE Per Bleeding Episode

    Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

    Time frame: Baseline (Day 0) up to end of study (up to 12.9 months)

07

Results

Posted Mar 7, 2024

Participant flow

Participants took part in the study at 4 investigative sites in India from 14 January 2022 to 10 February 2023.

Participant flow — Overall Study
MilestoneHemophilia A Group
Started50
Completed49
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. An SAE was defined as any untoward medical occurrence that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of present hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was a medically important event. Number of participants with SAEs (including FVIII inhibitor formation) that were at least possibly related to ADVATE were reported.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE
ParticipantsHemophilia A Group
Number of Participants With Serious Adverse Events (SAE) at Least Possibly Related to ADVATE0
SecondaryNumber of Participants With Non-serious Adverse Events (AEs) at Least Possibly Related to ADVATE

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product or medicinal product. Number of participants with non-serious AEs that were at least possibly related to ADVATE were reported.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AEs) at Least Possibly Related to ADVATE
ParticipantsHemophilia A Group
Number of Participants With Non-serious Adverse Events (AEs) at Least Possibly Related to ADVATE0
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Clinical laboratory parameters included hematology, clinical chemistry, viral serology, factor VIII (FVIII) antigen, FVIII activity, incremental recovery, and FVIII inhibitor. Clinical significance was judged as per Investigator's assessment.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsHemophilia A Group
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters0
SecondaryTotal Annualized Bleeding Rate (ABR) With Prophylactic Treatment of ADVATE

ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error was estimated using a generalized linear model (GLM). The total ABR is reported in this outcome measure.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · bleeds per year
Total Annualized Bleeding Rate (ABR) With Prophylactic Treatment of ADVATE
bleeds per yearHemophilia A Group
Total Annualized Bleeding Rate (ABR) With Prophylactic Treatment of ADVATE2.65 ± 0.195
SecondaryABR With Prophylactic Treatment of ADVATE Categorized Based on Location of Bleed

ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed sites (example, joint, soft tissue, muscle, other \[mouth, gums or nose\] are reported in this outcome measure.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · bleeds per year
ABR With Prophylactic Treatment of ADVATE Categorized Based on Location of Bleed
bleeds per yearHemophilia A Group
Bleed Location: Joint2.33 ± 0.203
Bleed Location: Soft Tissue0.04 ± 1.000
Bleed Location: Muscle0.16 ± 0.628
Bleed Location: Other (Mouth, Gums or Nose)0.12 ± 0.813
SecondaryABR With Prophylactic Treatment of ADVATE Categorized Based on Type of Bleed

ABR was defined as number of bleeding episodes during the study period divided by total number of study period days multiplied by 365.25. The mean ABR and standard error were estimated using a GLM. The ABR by bleed cause (example, spontaneous, injury, and unknown) are reported in this outcome measure.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · bleeds per year
ABR With Prophylactic Treatment of ADVATE Categorized Based on Type of Bleed
bleeds per yearHemophilia A Group
Bleed Type: Spontaneous1.86 ± 0.211
Bleed Type: Injury0.20 ± 0.692
Bleed Type: Unknown0.59 ± 0.541
SecondaryTotal Number of ADVATE Infusions Required During Prophylactic Treatment
Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · infusions
Total Number of ADVATE Infusions Required During Prophylactic Treatment
infusionsHaemophilia A Group
Total Number of ADVATE Infusions Required During Prophylactic Treatment65.8 ± 22.92
SecondaryAverage Number of ADVATE Infusions Required Per Week During Prophylactic Treatment
Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · infusions per week
Average Number of ADVATE Infusions Required Per Week During Prophylactic Treatment
infusions per weekHemophilia A Group
Average Number of ADVATE Infusions Required Per Week During Prophylactic Treatment2.5 ± 0.87
SecondaryAverage Number of ADVATE Infusions Required Per Month During Prophylactic Treatment of Bleeding Episode
Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · infusions per month
Average Number of ADVATE Infusions Required Per Month During Prophylactic Treatment of Bleeding Episode
infusions per monthHemophilia A Group
Average Number of ADVATE Infusions Required Per Month During Prophylactic Treatment of Bleeding Episode11.0 ± 3.76
SecondaryTotal Body Mass Adjusted Consumption of ADVATE During Prophylactic Treatment

Body mass adjusted consumption international units per kilograms (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · IU/kg
Total Body Mass Adjusted Consumption of ADVATE During Prophylactic Treatment
IU/kgHemophilia A Group
Total Body Mass Adjusted Consumption of ADVATE During Prophylactic Treatment1739.7 ± 621.18
SecondaryAverage Body Mass Adjusted Consumption of ADVATE Per Week During Prophylactic Treatment

Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · IU/kg per week
Average Body Mass Adjusted Consumption of ADVATE Per Week During Prophylactic Treatment
IU/kg per weekHemophilia A Group
Average Body Mass Adjusted Consumption of ADVATE Per Week During Prophylactic Treatment67.1 ± 24.12
SecondaryAverage Body Mass Adjusted Consumption of ADVATE Per Month During Prophylactic Treatment

Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · IU/kg per month
Average Body Mass Adjusted Consumption of ADVATE Per Month During Prophylactic Treatment
IU/kg per monthHemophilia A Group
Average Body Mass Adjusted Consumption of ADVATE Per Month During Prophylactic Treatment291.7 ± 104.80
SecondaryOverall Hemostatic Efficacy Rating of ADVATE for Treatment of Bleeding Episodes

Overall hemostatic efficacy for treatment of bleeding episodes was rated on 4-point Likert scale as: excellent=full relief of pain and cessation of objective signs of bleeding after a single infusion, no additional infusion is required for the control of bleeding and administration of further infusion to maintain hemostasis would not affect the scoring; good=definite pain relief and/or improvement in signs of bleeding after a single infusion, possibly requires more than 2 infusions for complete resolution and administration of further infusion to maintain hemostasis would not affect the scoring; moderate=probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion, required multiple infusions for complete resolution; none=no improvement of signs or symptoms or conditions worsen.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Number · bleeding episodes
Overall Hemostatic Efficacy Rating of ADVATE for Treatment of Bleeding Episodes
bleeding episodesHemophilia A Group
Excellent21
Good26
Moderate4
None0
SecondaryNumber of ADVATE Infusions Required to Achieve Resolution of Bleeding Episodes
Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · infusions
Number of ADVATE Infusions Required to Achieve Resolution of Bleeding Episodes
infusionsHemophilia A Group
Number of ADVATE Infusions Required to Achieve Resolution of Bleeding Episodes1.2 ± 0.46
SecondaryTotal Body Mass Adjusted Consumption of ADVATE Per Bleeding Episode

Body mass adjusted consumption (IU/kg) was derived as the total units infused (IU) divided by the last available body weight (kg) prior to the infusion.

Time frame:
Baseline (Day 0) up to end of study (up to 12.9 months)
Reported as:
Mean · IU/kg
Total Body Mass Adjusted Consumption of ADVATE Per Bleeding Episode
IU/kgHemophilia A Group
Total Body Mass Adjusted Consumption of ADVATE Per Bleeding Episode34.8 ± 19.79

Adverse events

Collected over Baseline (Day 0) up to end of study (up to 12.9 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hemophilia A Group0/50 (0%)0/50 (0%)6/50 (12%)
Most frequent other events
Most frequent other events
EventHemophilia A Group
PyrexiaGeneral disorders2/50
Skin lacerationInjury, poisoning and procedural complications2/50
VaricellaInfections and infestations1/50
Animal biteInjury, poisoning and procedural complications1/50
Joint injuryInjury, poisoning and procedural complications1/50

Baseline characteristics

Effectiveness Full Analysis Set (EFAS) comprised of all participants for whom all inclusion and none of the exclusion criteria were met.

Age, Continuous
Age, Continuous(years)Hemophilia A Group
Mean19.5 ± 13.01
Sex: Female, Male
Sex: Female, Male(Participants)Hemophilia A Group
Female0
Male50
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Hemophilia A Group
Hispanic or Latino0
Not Hispanic or Latino50
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hemophilia A Group
American Indian or Alaska Native0
Asian50
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Hemophilia A Group
India50
Weight
Weight(kilograms (kg))Hemophilia A Group
Mean48.5 ± 20.95
Height
Height(centimeters (cm))Hemophilia A Group
Mean152.0 ± 22.68
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter square (kg/m^2))Hemophilia A Group
Mean19.9 ± 5.42
08

Study locations

5 sites
  • Amrita Institute of Medical Science & Research Centre
    Ernakulam, Kerala 682041, India
  • St. John's Medical College
    Bengaluru, 560034, India
  • K J Somaiya Hospital & Research Centre
    Mumbai, 400022, India
  • All India Institute of Medical Sciences (AIIMS)
    New Delhi, 110029, India
  • Unique Children's Hospital Pvt. Ltd.
    Pune, 411019, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Feb 2023, 12 months.

Results were first posted in Mar 2024, 1 year after primary completion.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2021
First posted
Aug 2, 2021
StartActual
Jan 14, 2022
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Results first posted
Mar 7, 2024
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04985682
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Jan 14, 2022
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Results posted
Mar 7, 2024
Last update
Mar 7, 2024

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antihemophilic factor, human recombinant

Start the discussion